Clinical Trials Logo
  1. Home
  2. Germ Cell Tumor
  3. NCT03418844

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy — VIVROVAIRE TR  

Germ Cell Tumor Clinical Trial

Official title:
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Clinical Trial Summary

While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored. The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03418844
Study type Interventional
Source Centre Francois Baclesse
Contact
Status Active, not recruiting
Phase N/A
Start date May 7, 2018
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Terminated NCT00198172 - Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Phase 2
Recruiting NCT05874063 - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors Phase 3
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Completed NCT01466231 - Everolimus in Refractory Testicular Germ Cell Cancer Phase 2
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Recruiting NCT05889585 - Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
Recruiting NCT05394675 - A Study of DS-9606a in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03067181 - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Phase 3
Withdrawn NCT03960151 - Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Phase 2
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT03950830 - Disulfiram and Cisplatin in Refractory TGCTs. Phase 2
Recruiting NCT00898755 - Collecting and Storing Tissue From Young Patients With Cancer
Recruiting NCT04804007 - Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Phase 2
Terminated NCT02988843 - Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Phase 2
Recruiting NCT05259605 - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Active, not recruiting NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Phase 1
Recruiting NCT04308330 - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Phase 1
Recruiting NCT06418789 - High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors Phase 2